Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X.

@article{Wong1990HypotensiveAO,
  title={Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X.},
  author={Pancras C Wong and William A. Price and Andrew T. Chiu and John Jonas Vytautas Duncia and David John Carini and Ruth R. Wexler and A L Johnson and Pieter B.M.W.M. Timmermans},
  journal={Hypertension},
  year={1990},
  volume={15 5},
  pages={
          459-68
        }
}
In conscious 18-21-week-old spontaneously hypertensive rats, DuP 753, a nonpeptide angiotensin II receptor antagonist, given orally at 3 and 10 mg/kg or intravenously at 3, 10, and 30 mg/kg, reduced blood pressure dose dependently. It did not alter heart rate at these doses. At 10 mg/kg i.v., DuP 753 decreased blood pressure significantly for at least 24 hours, suggesting a long duration of the antihypertensive effect. Unlike saralasin, DuP 753 did not cause a transient increase in blood… 
Prolonged Angiotensin II Antagonism in Spontaneously Hypertensive Rats: Hemodynamic and Biochemical Consequences
TLDR
The results indicate that the antihypertensive effects of converting enzyme inhibitors in spontaneously hypertensive rats are mainly due to the blockade of the renin-angiotensin system.
Kidney is an important target for the antihypertensive action of an angiotensin II receptor antagonist in spontaneously hypertensive rats.
TLDR
Exogenous angiotensin II acting within the kidney appears to play an important role in the maintenance of high blood pressure in spontaneously hypertensive rats.
Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II
TLDR
DuP 753 appears to be a well-tolerated, orally active, potent, and long-lasting antagonist of angiotensin II in men.
The neurogenic origin of hypertension in SHR may be mediated by angiotensin II through a receptor different from AT1 and AT2
TLDR
In the CNS of the young SHR, an active Renin-Ang-System is implicated in the establishment of the hypertensive state, and that the receptor for this function is different from AT1 and AT2, since it has a selectivity profile different from At1 andAT2 receptor types.
Effects of Angiotensin Subtype 1 and Subtype 2 Receptor Antagonists in Normotensive Versus Hypertensive Rats
TLDR
Data indicate that in both hypertensive and control rats, AT2 receptors mediate the acute effects of angiotensin II on arterial blood pressure, aldosterone release, and mesenteric vascular resistance, and spontaneously hypertensive rats are more sensitive to DuP 753-induced blockade of angiotsin II-mediated ald testosterone release.
Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two‐kidney, one‐clip Goldblatt hypertensive rats
TLDR
ZD7155 is a potent antihypertensive agent in two-kidney, one-clip Goldblatt hypertensive rats and this effect is accompanied by sustained inhibition of tissue angiotensin II binding.
Effects of renin-angiotensin system blockade in guinea pigs.
TLDR
It is concluded that in furosemide-treated guinea pigs, as opposed to previously published animal models, the decrease of arterial pressure induced by angiotensin converting enzyme inhibitors may be partly due to extrarenal effects not related to the renin-angiotens in system.
Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs.
TLDR
Results suggest that the AT1 receptor mediates the pressor and renal effects of AII in dogs, and that the acute transient hypotensive effect of DuP 753 in normal-renin conscious dogs is probably unrelated to AII antagonism.
Peripheral vs. central blockade of the renin-angiotensin system in spontaneously hypertensive rats: comparison of novel AT1 receptor antagonist TCV-116 with angiotensin converting enzyme inhibitor delapril
TLDR
The findings suggest that the depressor properties of orally administered delapril are more complex than those of TCV-116, while central blockade by both angiotensin converting enzyme and AT1 receptor decreases blood pressure in part through baroreceptor sensitization.
Contribution of nitric oxide to the acute antihypertensive effect of blockers of AT1 angiotensin receptors in spontaneously hypertensive rats.
TLDR
It is suggested that a mechanism mediated by NO and/or cGMP is necessary for the full expression of the acute antihypertensive effect of AT1 angiotensin receptor blockers in SHR.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.
TLDR
In conscious renal artery-ligated rats, a high renin hypertensive rat model, DuP 753, a p.o.v. active nonpeptide angiotensin II (AII) receptor antagonist, decreased blood pressure and inhibited the pressor response to AII but not to norepinephrine or vasopressin, similar to that of captopril.
Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
In the spinal pithed rat, DuP 753, 2-n-butyl-4-chloro-5-hydroxy-methyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl) methyl] imidazole potassium salt, inhibited competitively the pressor response to
Hypotensive action of angiotensin I converting enzyme inhibitor (SQ 14,225) in nephrectomized dogs.
TLDR
In anesthetized dogs, intrarenal and i.v. infusion of SQ 14,225 at a rate of 0.5 mg/min resulted in a significant and similar fall in systemic blood pressure, which would suggest that the renin-angiotensin system plays a relatively minor role in the blood pressure reduction in normotensive anesthenized dogs.
Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats.
TLDR
Results indicate that chronic inhibition of ACE with captopril induces normalization of blood pressure in SHR, a normal-renin model of hypertension.
Hypotensive Action of Captopril and Saralasin in Intact and Anephric Spontaneously Hypertensive Rats
TLDR
Results indicate that captopril and saralasin lower blood pressure in the SHR by some mechanism(s) independent of the kidneys, circulating renin, or bradykinin potentiation, and it is suggested that angiotensin II, locally produced at some critical tissue site(s), is involved in the maintenance of raisedBlood pressure in SHR.
Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.
TLDR
The data demonstrate that DuP 753, is a potent and highly specific angiotensin II receptor antagonist and may be a useful experimental or therapeutic tool for interference with the renin-angiotens in system in health and diseases.
Role of the Pressor Action of Angiotensin IIin Experimental Hypertension
TLDR
The data indicate that, under certain experimental conditions, the blood pressure of rats during the acute phase of unilateral renal hypertension is maintained hy the endogenous angiotensin II, which was previously demonstrated to he present in the plasma in supernormal concentrations.
Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme.
TLDR
The results suggest that SQ 14,225 acts primarily by inhibiting the renin-angiotensin system to reduce elevated blood pressure, especially in presumably ren in-dependent models of hypertension.
Studies on the mechanism of the hypotensive action of SQ-14225, an angiotensin-converting enzyme inhibitor in anesthetized dogs.
TLDR
The results suggest that the hypotensive action of SQ-14225 in the pentobarbital-anesthetized dog may be unrelated to the renal renin-angiotensin system.
Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308.
TLDR
S-8308 is a weak, but specific and competitive, non-peptide antagonist of AII exerting its inhibitory action at the receptor level, and shows no affinity for alpha 1-adrenoceptors or Ca2+ channels.
...
1
2
3
4
5
...